Search
for
Sort by
Research 301–330 of 1000+
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Fractionated CO2 Laser in Combination with Topical Tacrolimus for Chronic Alopecia Areata: A Case Series Study
- Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- JAK inhibitors and alopecia areata
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Vitiligo
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- JAK Inhibitors for Treatment of Alopecia Areata